Table III.
Association between MMP1 polymorphisms with chronic obstructive pulmonary disease (COPD) and/or non-small cell lung cancer (NSCLC), Maryland Lung Cancer Study, 1998–2004.
| Race | Polymorphism | Exposed/Unexposed | Controls N | COPD cases | NSCLC cases | COPD plus NSCLC cases | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| N | OR (95% CI)1,3 | N | OR (95% CI)1,4 | N | OR (95% CI)1,4 | OR (95% CI)2,4 | ||||
| African-American | ||||||||||
| rs1799750** | 1G-2G/1G-1G | 77/44 | 24/12 | 1.18 (0.53, 2.63) | 31/23 | 0.91 (0.45, 1.86) | 12/5 | 3.42 (0.83, 14.14) | 1.16 (0.23, 5.74) | |
| 2G-2G/1G-1G | 26/44 | 8/12 | 1.22 (0.43, 3.45) | 17/23 | 1.24 (0.53, 2.91) | 9/5 | 5.48 (1.17, 25.72) | 3.03 (0.50, 18.29) | ||
| rs10488 | AG+AA/GG | 29/118 | 10/34 | 1.52 (0.65, 3.56) | 19/52 | 1.78 (0.85, 3.71) | 8/18 | 2.48 (0.82, 7.44) | 2.46 (0.63, 9.65) | |
| rs470558 | AG+AA/GG | 3/144 | 4/40 | 4.52 (0.94, 21.84) | 4/67 | 2.11 (0.43, 10.36) | 0/26 | -- | -- | |
| rs5031036 | AG+GG/AA | 36/111 | 12/32 | 1.42 (0.64, 3.14) | 22/49 | 1.67 (0.84, 3.35) | 8/18 | 1.90 (0.65, 5.57) | 1.70 (0.46, 6.33) | |
| rs2071230 | CT+CC/TT | 63/84 | 15/29 | 0.67 (0.33, 1.38) | 33/38 | 1.13 (0.61, 2.09) | 13/13 | 1.31 (0.49, 3.47) | 1.37 (0.43, 4.39) | |
| rs5854 | CT+TT/CC | 67/80 | 18/26 | 0.81 (0.40, 1.63) | 25/46 | 0.68 (0.36, 1.27) | 12/14 | 1.10 (0.42, 2.90) | 1.87 (0.57, 6.15) | |
| Caucasian | rs1799750** | 1G-2G/1G-1G | 91/48 | 51/39 | 0.71 (0.37, 1.36) | 86/52 | 0.84 (0.48, 1.47) | 48/30 | 1.23 (0.58, 2.63) | 1.26 (0.67, 2.38) |
| 2G-2G/1G-1G | 52/48 | 33/39 | 0.69 (0.33, 1.41) | 33/52 | 0.70 (0.36, 1.36) | 24/30 | 1.15 (0.49, 2.68) | 0.89 (0.43, 1.86) | ||
| rs10488 | AG+AA/GG | 18/173 | 16/107 | 1.71 (0.72, 4.08) | 17/154 | 1.16 (0.52, 2.61) | 7/95 | 0.92 (0.28, 3.03) | 0.49 (0.19, 1.26) | |
| rs470558 | AG+AA/GG | 24/167 | 14/109 | 0.99 (0.43, 2.27) | 20/151 | 0.73 (0.36, 1.49) | 13/89 | 1.38 (0.55, 3.44) | 1.34 (0.58, 3.10) | |
| rs5031036 | AG+GG/AA | 18/173 | 16/107 | 1.37 (0.58, 3.20) | 17/154 | 1.08 (0.49, 2.40) | 9/93 | 1.11 (0.38, 3.28) | 0.64 (0.27, 1.56) | |
| rs2071230 | CT+CC/TT | 23/168 | 22/100 | 1.40 (0.67, 2.92) | 30/141 | 1.72 (0.88, 3.37) | 22/80 | 2.51 (1.09, 5.77) | 1.26 (0.64, 2.47) | |
| rs5854 | CT/CC | 88/75 | 47/58 | 0.59 (0.33, 1.07) | 84/62 | 0.98 (0.58, 1.64) | 46/42 | 0.57 (0.29, 1.13) | 1.15 (0.63, 2.08) | |
| TT/CC | 28/75 | 18/58 | 0.74 (0.33, 1.68) | 25/62 | 1.10 (0.53, 2.28) | 14/42 | 0.50 (0.18, 1.35) | 1.04 (0.45, 2.38) | ||
1
Compared to controls or
2
COPD-only cases
3
adjusted for smoking status (never, former, current) and pack-years (continuous) truncated at COPD diagnosis or
4
adjusted for smoking status (never, former, current) and pack-years (continuous) at enrollment, all MMP1 variables were included in the same model.
**
Also referred to in the literature as rs11292517.